Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wider use of statins is a “no-brainer”

This article was originally published in Scrip

Executive Summary

A few weeks ago NICE, the health technology body for England and Wales, issued new draft guidance on the use of statins in people considered to be at relatively low risk of cardiovascular diseases such as heart disease, stroke and peripheral arterial disease (scripintelligence.com, 13 February 2014). NICE is recommending that the threshold for starting preventive treatment of these conditions should be halved from a 20% risk of developing CVD over 10 years to a 10% risk.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC024849

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel